AstraZeneca plc. is multinational biologics and pharmaceutical company. It is headquartered in London in UK.
Image: company website
In terms of prescription sales it is one of the largest company in the world and it was followed after Pfizer, Sanofi, Novartis, Merck & Co., Roche and GlaxoSmithKline. It has operation in more than 100 countries and has a huge portfolio of products for major diseases including cancer, neuroscience, respiratory , cardiovascular, gastrointestinal, infection and inflammation.
The company’s history dates back to 1999 when it was founded by the merger between UK based Zeneca Group and the Sweden-based Astra AB. It has since then made numerous corporate acquisitions like MedImmune (in 2007), Cambridge Antibody Technology (in 2006), Definiens (by MedImmune in 2014) and Spirogen (in 2013).
This company has primary listing on London Stock Exchange. It is also a constituent of FTSE 100 Index with secondary listings on OMX exchange and New York Stock Exchange. Recently in news reported that a drug from AstraZeneca is a breakthrough drug in cancer. It has shown promising results for women suffering from ovarian cancer. An interim study looking at early findings claimed that long-term survival of women who are taking olaparib, famously known by its brand name Lynparza, suggested that drug is increasing the life-expectancy.
This claim was verified by Dr Mene Pangalos who is the executive Vice President at AstraZeneca. He verified this to delegates present at conference which was held in Chicago and is referred by American Society of Clinical Oncology's. Dr. Pangalos who joined AstraZeneca was given the task of igniting the discovery engine when its string of bestselling medicines lost its exclusivity.